Table 3: Baseline characteristics of TAI with DEB-TACE in the second-line group or in the follow-up group after lenvatinib treatment.
|
|
Second line |
Follow up |
p-value |
|
Mean age (years, range) |
77.00±7.45 |
76.14±7.46 |
p=0.7838 |
|
Sex (male/female) |
3/2 |
3/4 |
p=0.5582 |
|
Etiology (HBV/HCV/NBNC) |
1/4/0 |
0/5/2 |
p=0.2397 |
|
Child-Pugh score (5/6) |
2/3 |
3/4 |
p=0.9212 |
|
ALBI grade (1/2) |
2/3 |
3/4 |
p=0.9212 |
|
BCLC (B/C) |
0/5 |
0/7 |
p=1.000 |
|
Portal vein tumor thrombosis (present/absent) |
2/3 |
3/4 |
p=0.9212 |
|
Extrahepatic spread (present/absent) |
2/3 |
3/4 |
p=0.9212 |
|
AFP (ng/mL) |
193.20±92.87 |
110.35±71.33 |
p=0.4285 |
|
DCP (mAU/mL) |
801.22±417.63 |
127.27±68.04 |
p=0.1113. |
HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; NBNC: Non-HBV and Non-HCV; ALBI: Albumin-Bilirubin; BCLC: Barcelona Cancer Liver Clinic; CONUT: Controlling Nutritional Status; AFP: Alpha-Fetoprotein; DCP: Des-Gamma Carboxy-Prothrombin; n.s.: not significant.